The Lachman Blog

Subscribe to our blog

14
Feb

Association for Accessible Medicines –  What is This?

Today, at the Generic Pharmaceutical Association (GPhA) Annual Meeting, Chip Davis, the CEO of the “former” GPhA announced the rebranding of the association to its new name, the Association for Accessible Medicines (aam).  The change is designed to further the work of the industry group to provide more affordable medicines in both the generic and […]

Read More
13
Feb

OMB Clarifies Hiring Freeze for FDA

A memo and its attachments was issued on February 6, 2017 to give various position classes, including pharmacist, consumer safety officers, microbiologists, chemists, medical officers, etc., which cover many of the FDA position classifications. Also, there is no freeze of the hiring of Commissioned Corps Officers of the United States Public Health Service. Hopefully, this […]

Read More
09
Feb

States Getting into Pricing Issues – Look Out Below!

Seems like every day we see new proposed legislation being introduced into another state’s legislature.  Each one seems to have a somewhat different methodology or focus for controlling and reporting on drug prices.  Let’s think about this.  Everyone wants to strive for lower drug prices.  Remember, in the early 1980’s, the entire nation was focused […]

Read More
06
Feb

May Not Be a Rash Decision to Worry About a Rash

The FDA issued a safety warning on Thursday afternoon regarding the potential for rare but serious adverse reactions (including anaphylaxis, hives and severe rash) for a common skin sanitizing agent.  The warning focuses on chlorhexidine gluconate which is available both as a prescription and over-the-counter product for use as a skin sanitizer.  In addition, the […]

Read More
02
Feb

Let’s See if We Get this Right

Remember the old FDA Monthly Approvals Report that never really provided numbers that matched the approvals that OGD reported in their Activities Report of the Generic Drug Program (Activities Report)?  (see story here). We reported a usual 5-10% discrepancy relative to approvals between the reports.  Well, the FDA Monthly Approval Report was discontinued many months […]

Read More
1 156 157 158 212